[go: up one dir, main page]

BRPI0409366A - compostos de pirimido - Google Patents

compostos de pirimido

Info

Publication number
BRPI0409366A
BRPI0409366A BRPI0409366-6A BRPI0409366A BRPI0409366A BR PI0409366 A BRPI0409366 A BR PI0409366A BR PI0409366 A BRPI0409366 A BR PI0409366A BR PI0409366 A BRPI0409366 A BR PI0409366A
Authority
BR
Brazil
Prior art keywords
compounds
pyrimidine compounds
kdr
colon
lung
Prior art date
Application number
BRPI0409366-6A
Other languages
English (en)
Inventor
Yi Chen
Apostolos Dermatakis
Jin-Jun Liu
Kin-Chun Luk
Christophe Michoud
Pamela Loreen Rossman
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0409366A publication Critical patent/BRPI0409366A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

"COMPOSTOS DE PIRIMIDO". A presente invenção refere-se a novos compostos de pirimido da fórmula: que são inibidores seletivos das cinases KDR e FGFR. Esses compostos e seus sais farmaceuticamente aceitáveis são agentes antiproliferativos usados no tratamento ou controle de tumores sólidos, em particular, tumores de mama, cólon, pulmão e próstata. Também descritas são composições farmacêuticas contendo esses compostos e o uso para tratamento de câncer.
BRPI0409366-6A 2003-04-10 2004-04-01 compostos de pirimido BRPI0409366A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46169403P 2003-04-10 2003-04-10
PCT/EP2004/003447 WO2004089955A1 (en) 2003-04-10 2004-04-01 Pyrimido compounds

Publications (1)

Publication Number Publication Date
BRPI0409366A true BRPI0409366A (pt) 2006-04-25

Family

ID=33159829

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409366-6A BRPI0409366A (pt) 2003-04-10 2004-04-01 compostos de pirimido

Country Status (11)

Country Link
US (1) US7115740B2 (pt)
EP (1) EP1615928A1 (pt)
JP (1) JP2006522756A (pt)
KR (2) KR20050111636A (pt)
CN (1) CN100497339C (pt)
AU (1) AU2004228155A1 (pt)
BR (1) BRPI0409366A (pt)
CA (1) CA2521124A1 (pt)
MX (1) MXPA05010765A (pt)
RU (1) RU2350617C2 (pt)
WO (1) WO2004089955A1 (pt)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06001098A (es) * 2003-07-29 2006-04-24 Irm Llc Compuestos y composiciones utiles como inhibidores de proteina cinasa.
AU2005302608A1 (en) * 2004-10-28 2006-05-11 Merck & Co., Inc. Pyrimidine and quinoline potentiators of metabotropic glutamate receptors
WO2007060140A2 (en) * 2005-11-28 2007-05-31 F. Hoffmann-La Roche Ag Inhibitors of diacyglycerol acyltransferase (dgat)
EP1981886B1 (en) 2006-01-31 2009-08-12 F.Hoffmann-La Roche Ag 7h-pyrido[3,4-d]pyrimidin-8-ones, their manufacture and use as protein kinase inhibitors
WO2010067888A1 (en) * 2008-12-12 2010-06-17 Banyu Pharmaceutical Co.,Ltd. Dihydropyrimidopyrimidine derivatives
JP2012511502A (ja) 2008-12-12 2012-05-24 Ｍｓｄ株式会社 ジヒドロピリミドピリミジン誘導体
WO2010099139A2 (en) 2009-02-25 2010-09-02 Osi Pharmaceuticals, Inc. Combination anti-cancer therapy
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
JP2012519281A (ja) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
US8465912B2 (en) 2009-02-27 2013-06-18 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
SG10201702654VA (en) * 2011-04-22 2017-06-29 Signal Pharm Llc Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
WO2013018733A1 (ja) 2011-07-29 2013-02-07 富士フイルム株式会社 １，５－ナフチリジン誘導体又はその塩
GB201204384D0 (en) 2012-03-13 2012-04-25 Univ Dundee Anti-flammatory agents
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
CN107652289B (zh) 2012-06-13 2020-07-21 因塞特控股公司 作为fgfr抑制剂的取代的三环化合物
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
AR094812A1 (es) 2013-02-20 2015-08-26 Eisai R&D Man Co Ltd Derivado de piridina monocíclico como inhibidor del fgfr
KR102350704B1 (ko) * 2013-03-15 2022-01-13 셀젠 카르 엘엘씨 헤테로아릴 화합물 및 이의 용도
CN111793068A (zh) * 2013-03-15 2020-10-20 西建卡尔有限责任公司 杂芳基化合物和其用途
TWI647220B (zh) 2013-03-15 2019-01-11 美商西建卡爾有限責任公司 雜芳基化合物及其用途
KR102269032B1 (ko) 2013-04-19 2021-06-24 인사이트 홀딩스 코포레이션 Fgfr 저해제로서 이환식 헤테로사이클
US10457691B2 (en) 2014-07-21 2019-10-29 Dana-Farber Cancer Institute, Inc. Macrocyclic kinase inhibitors and uses thereof
US10287268B2 (en) 2014-07-21 2019-05-14 Dana-Farber Cancer Institute, Inc. Imidazolyl kinase inhibitors and uses thereof
EP3177295A4 (en) 2014-08-08 2018-06-13 Dana Farber Cancer Institute, Inc. Uses of salt-inducible kinase (sik) inhibitors
ES2914072T3 (es) 2014-08-18 2022-06-07 Eisai R&D Man Co Ltd Sal de derivado de piridina monocíclico y su cristal
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
PE20171514A1 (es) 2015-02-20 2017-10-20 Incyte Corp Heterociclos biciclicos como inhibidores de fgfr
JP6503450B2 (ja) 2015-03-25 2019-04-17 国立研究開発法人国立がん研究センター 胆管癌治療剤
MX384034B (es) 2015-12-17 2025-03-14 Eisai R&D Man Co Ltd Agente terapeutico para cancer de mama.
CN110225914A (zh) * 2016-07-05 2019-09-10 布罗德研究所股份有限公司 双环脲激酶抑制剂及其用途
WO2018053373A1 (en) 2016-09-16 2018-03-22 The General Hospital Corporation Uses of satl-inducible kinase (sik) inhibitors for treating osteoporosis
BR112019017741A2 (pt) 2017-02-28 2020-04-07 Dana Farber Cancer Inst Inc usos de pirimidopirimidinonas como inibidores de sik
CN110809576B (zh) * 2017-03-03 2022-08-30 奥克兰联合服务有限公司 Fgfr激酶抑制剂和药物用途
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CN109384790B (zh) * 2017-08-08 2022-05-10 药捷安康(南京)科技股份有限公司 成纤维细胞生长因子受体抑制剂及其用途
CN109836427B (zh) * 2017-11-29 2022-04-15 暨南大学 嘧啶并嘧啶酮类化合物及其应用
BR112020017922A2 (pt) 2018-03-28 2020-12-22 Eisai R&D Management Co., Ltd. Agente terapêutico para carcinoma hepatocelular
BR112020022373A2 (pt) 2018-05-04 2021-02-02 Incyte Corporation sais de um inibidor de fgfr
SG11202010636VA (en) 2018-05-04 2020-11-27 Incyte Corp Solid forms of an fgfr inhibitor and processes for preparing the same
CN113474347A (zh) * 2018-12-27 2021-10-01 法国施维雅药厂 Mat2a的aza杂双环抑制剂和用于治疗癌症的方法
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
GB201908511D0 (en) 2019-06-13 2019-07-31 Adorx Therapeutics Ltd Hydroxamate compounds
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021076602A1 (en) 2019-10-14 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
GB201915828D0 (en) 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
JP7720840B2 (ja) 2019-12-04 2025-08-08 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式複素環
CN115151539A (zh) 2019-12-04 2022-10-04 因赛特公司 Fgfr抑制剂的衍生物
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US12065494B2 (en) 2021-04-12 2024-08-20 Incyte Corporation Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent
CA3220155A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
AR126102A1 (es) 2021-06-09 2023-09-13 Incyte Corp Heterociclos tricíclicos como inhibidores de fgfr
KR20240115979A (ko) 2021-11-08 2024-07-26 프로젠토스 테라퓨틱스, 인크. 혈소판-유래 성장 인자 수용체(pdgfr) 알파 억제제 및 이의 용도
WO2025109026A1 (en) 2023-11-21 2025-05-30 Intervet International B.V. Process for the preparation of 4-fluoro-3-methoxyaniline

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2949466A (en) 1958-03-04 1960-08-16 Parke Davis & Co Pyrimidine compounds and means of producing the same
NL6704601A (pt) 1966-04-06 1967-10-09
US4425346A (en) 1980-08-01 1984-01-10 Smith And Nephew Associated Companies Limited Pharmaceutical compositions
JPS60226882A (ja) 1984-04-24 1985-11-12 Nippon Zoki Pharmaceut Co Ltd 新規ピリミドピリミジン誘導体
WO1998024432A2 (en) 1996-12-05 1998-06-11 Sugen, Inc. Use of indolinone compounds as modulators of protein kinases
KR20010043829A (ko) * 1998-05-26 2001-05-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 세포 증식 억제제로서의 비시클릭 피리미딘 및 비시클릭3,4-디히드로피리미딘
HRP20010274A2 (en) * 1998-10-23 2002-06-30 Hoffmann La Roche Bicyclic nitrogen heterocycles
WO2001029042A1 (en) 1999-10-21 2001-04-26 F. Hoffmann-La Roche Ag Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase
KR100537241B1 (ko) * 1999-10-21 2005-12-19 에프. 호프만-라 로슈 아게 Ｐ38 단백질 키나제의 억제제로서의 알킬아미노 치환된이중고리 질소 헤테로고리 화합물
AR030053A1 (es) 2000-03-02 2003-08-13 Smithkline Beecham Corp 1h-pirimido [4,5-d] pirimidin-2-onas y sales, composiciones farmaceuticas, uso para la fabricacion de un medicamento y procedimiento para producirlas
AU2001293784B2 (en) 2000-08-31 2007-08-30 F. Hoffmann-La Roche Ag 7-OXO pyridopyrimidines as inhibitors of a cellular proliferation
ES2251677T3 (es) 2002-01-22 2006-05-01 Warner-Lambert Company Llc 2-(piridin-2-ilamino)-pirido(2,3-d)pirimidin-7-onas.
PA8577501A1 (es) 2002-07-25 2004-02-07 Warner Lambert Co Inhibidores de quinasas
WO2004041285A1 (en) 2002-10-31 2004-05-21 Amgen Inc. Antiinflammation agents

Also Published As

Publication number Publication date
AU2004228155A1 (en) 2004-10-21
KR20070087053A (ko) 2007-08-27
KR100864393B1 (ko) 2008-10-20
WO2004089955A1 (en) 2004-10-21
CA2521124A1 (en) 2004-10-21
US7115740B2 (en) 2006-10-03
CN100497339C (zh) 2009-06-10
US20040204427A1 (en) 2004-10-14
KR20050111636A (ko) 2005-11-25
RU2005134686A (ru) 2006-07-27
EP1615928A1 (en) 2006-01-18
CN1809569A (zh) 2006-07-26
MXPA05010765A (es) 2005-12-12
RU2350617C2 (ru) 2009-03-27
JP2006522756A (ja) 2006-10-05

Similar Documents

Publication Publication Date Title
BRPI0409366A (pt) compostos de pirimido
BR0315912A (pt) Compostos pirimìdicos com atividade antiproliferativa (ii)
TW200407326A (en) Pyrimido compounds having antiproliferative activity
BR0317480A (pt) Derivados de piridino[2,3-d]pirimidina como inibidores kdr e fgfr seletivos
BRPI0511975A (pt) pirazolopirimidinas
BR0206496A (pt) Diaminotiazóis
JO2248B1 (en) Pirazolobenzodiazepines
IL191832A (en) Pyridiazinone compounds and their use in the preparation of drugs for the treatment of tumors
IL260127B (en) mek inhibitors and methods of using them
MXPA05007352A (es) Compuestos triciclicos inhibidores de proteina quinasa para mejorar la eficacia de agentes antineoplasicos y terapia de radiacion.
BR0308030A (pt) Derivados de 5-feniltiazol e uso como inibidores de pi3 cinase
BR0215360A (pt) Derivados de indolina úteis como inibidores de proteìna quinase
BRPI0407834A (pt) composto, processo para a manufatura do mesmo, composição, processo para a manufatura da mesma, método de tratamento ou prevenção de um distúrbio mediado por proteìna quinase em um indivìduo, uso de um composto, ensaio para determinar a atividade dos compostos, e, método de inibição da atividade ou função de uma proteìna quinase
CL2008000785A1 (es) Compuestos derivados de 4-((7,7-difluoro-5-metil-6-oxo-6,7,8,9-tetrahidro-5h-pirimido[4,5-b][1,4]diazepin-2-il)amino)-3-metoxibenzamida; compuesto intermediario; composicion farmaceutica, utiles para tratar el cancer.
BR0309343A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
BRPI0415525A (pt) derivados de imidazola e seu uso como agentes farmacêuticos
BR0309342A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
BR0310081A (pt) Diaminotiazóis úteis como inibidores seletivos de cdk4
ATE287886T1 (de) Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b) pyridinen als cyclin- abhängige kinase-hemmer
EA200501233A1 (ru) 4-аминопиримидин-5-он
BR0309996A (pt) Composto, composição farmacêutica, método de tratar ou melhorar doenças ou condições proliferativas, uso de um composto, e, método de tratar ou melhorar doenças inflamatórias
MXPA06007007A (es) Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores.
BRPI0520482A2 (pt) amidas do ácido 4-amino-tieno [3,2-c] piridina-7-carboxìlico
BRPI0510001A (pt) diaminotiazóis substituìdos na piperidina
UY26498A1 (es) Pirroles sustituidos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.